An­a­lysts cheer as Ab­b­Vie pays $750M cash to al­ly it­self with Gen­mab on a pipeline of can­cer drugs, with bil­lions more on the ta­ble

You can count the R&D ex­ecs at Ab­b­Vie among the be­liev­ers in Gen­mab’s bis­pe­cif­ic plat­form tech.

Mov­ing be­yond the Al­ler­gan buy­out, Ab­b­Vie re­fo­cused on its can­cer drug pipeline, shelling out $750 mil­lion in cash and promis­ing up to $3.15 bil­lion more in mile­stones — 60% for de­vel­op­ment and reg­u­la­to­ry goals — to al­ly it­self on a slate of 7 de­vel­op­ment and dis­cov­ery pro­grams.

At the front of the queue is the ear­ly-stage drug ep­cori­ta­m­ab, a CD3xCD20 bis­pe­cif­ic from its Duo­Body col­lec­tion. There’s al­so Duo­Hexa­Body-CD37 and Duo­Body-CD3x5T4. And then Ab­b­Vie gets to pick and choose from among the dis­cov­ery work at Gen­mab for 4 more, with Ab­b­Vie adding in its own con­tri­bu­tions in the pair­ing up to come.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER